Large numbers of people in low-income countries face COVID unprotected, and millions of people would still be alive today if they had had access to a vaccine. Big pharma corporations have been given free rein to prioritize profits ahead of vaccine equality as the richest ten men doubled their fortunes during the pandemic. A new billionaire is being created every 26 hours profiting from vaccines, treatments, tests, etc. PPE. When is enough enough?
Press Ganey recently asked1 1,000+ healthcare consumers about their digital behaviors, but unfortunately, their findings mean little to emarketers working within the industry. They are somewhat embarrassing.
Over 73% of patients plan to continue using telemedicine platforms post-pandemic, according to Doximity’s second edition of its State of Telemedicine Report, which was released today. As part of the report, Doximity, the leading digital platform for U.S. medical professionals, analyzed the adoption of telemedicine across its physician user base from January 2020 through June 2021 and conducted a study of patients’ experiences with telemedicine during the same time frame. This self-serving report is flawed.
Advertising is meant to “sell” your product, but the pharma industry is unique because people don’t just see an ad for a prescription drug and run to their doctor. There is a path between awareness and asking for/receiving an Rx. It’s more than just about understanding; it’s about being relevant to the needs of online health seekers.
Ninety-two percent of U.S. viewers surveyed in 2021 believe “they see the same advertisements too many times when watching TV,” according to a new study by Audience Project. Nowhere is this more evident than in pharma TV ads like Tepezza.
Pfizer expects to make as much as $22bn from its new Covid pill this year, on top of $37bn it made in 2021 from the vaccine. Pfizer’s Paxlovid currently costs about $530 for a five-day course of the treatment. Merck’s molnupiravir, now approved for use in the U.K., costs about $700. Reportedly, the cost of production for molnupiravir stands at about $17.74. Experts across the board are predicting demand for antiviral drugs will rapidly outpace supply.
Business Insider formed a relationship with eMarketer for so-called “intelligence.” Their report on telehealth has numbers, but that’s not what’s important. We need to understand “why” people are using telehealth and for what purposes versus an in-office visit. In-office visits also have more benefits.
COVID may be winding down, but the damage is done in deaths and long COVID. We don’t understand much, but we do know that there is a correlation between COVID severity and obesity/diabetes. The question thus becomes, “will the medical community finally address the obesity epidemic, or will we continue to do nothing essentially?”.